2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
26
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
8
Adenocarcinoma
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
HER2-positive Breast Cancer
3
Advanced Solid Tumor
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm, Residual
2
Meningeal Carcinomatosis
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Interventions
Cisplatin
182
Radiotherapy
81
Paclitaxel
80
Brachytherapy
74
Carboplatin
72
pembrolizumab
63
Bevacizumab
40
Surveys and Questionnaires
29
Colposcopy
29
Radiation
28
Gemcitabine
28
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
27
Topotecan
26
Magnetic Resonance Spectroscopy
24
Blood Specimen Collection
23
human papillomavirus vaccine, L1 type 16, 18
22
Nivolumab
22
Drug Therapy
22
Papillomavirus Vaccines
20
atezolizumab
19
Platinum
19
Radiotherapy, Intensity-Modulated
18
Biopsy
18
Docetaxel
17
Taxes
16
Cyclophosphamide
16
Early Intervention, Educational
15
1,2-diaminocyclohexaneplatinum II citrate
15
Methods
14
fludarabine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled